Bioveritas Partners at PharmaTech Integrates 2026, Glasgow
Updated: Nov 5
On 2 October 2026, Bioveritas Partners joined the pharmaceutical manufacturing and technology community at PharmaTech Integrates 2026, held at the University of Strathclyde's Technology & Innovation Centre in Glasgow. We were proud to take part as an Event Partner, with our own stand and four of our team on the ground: founders Dr Arunesh Sil and Rod Grundy, and Senior Consultants Barry Daly and Henrik Schou.

A programme built for what comes next
This year's theme was "Built for the Future – Broad Modalities, Smarter Systems, and the Next Era of Pharma Technology". Organised by Life Science Integrates, the day brought together innovators, regulators, supply chain partners, technology providers and academia.
The keynote came from Professor Stephen McArthur, Principal and Vice-Chancellor of the University of Strathclyde. The opening fireside chat, "Built for the Patient: Is Pharma Manufacturing Ready?", set the tone, with Professor Yvonne Perrie MBE, Ian McCubbin CBE, Nicola Heron of Medicines Discovery Catapult and Stuart Richardson of AstraZeneca.
From there the agenda moved through the questions shaping the sector:
Agentic AI: "Beyond Pilots" brought together voices from AstraZeneca, the MHRA, Merz Therapeutics, Helfie AI and QbDVision, chaired by PwC.
Process intensification: "The Intensification Gap" featured CMAC, Newcastle University, AstraZeneca, Bridge CMC and Pharmagro.
Data sharing: "Unlocking Pharma's Collective Intelligence" heard from Roche, GSK, Pfizer and Digital Technologies Group.
Sustainability: "The Green Advantage" included Evotec, Britest, Schneider Electric and Disyn Biotec.
The closing fireside, "Pharma's Next Chapter", featured Professor Alastair Florence of CMAC alongside leaders from Novo Nordisk and GSK.
Why it matters to us
Technology only delivers for patients when it is adopted responsibly. That was most visible in the AI discussion, where a regulator and a market access leader shared the platform with the technologists. New tools change how evidence is generated, how medicines are made and how companies talk about them. Each of those steps carries compliance, medical and commercial consequences.
That is the ground Bioveritas Partners works on. Whether a company is preparing a launch, building a field medical team or putting materials through ABPI Code review, the same principle applies: move quickly, and get the detail right.
A friendly challenge on AI
For me, the best part of the day was the conversations at our stand. Many of them came back to the same question: how can AI be integrated into drug development where it will have the greatest impact?
I put a friendly challenge to several of the people I spoke to: over the years I have been offered a lot of AI and tech solutions for problems I do not have. It usually raised a smile, and then a better conversation. The most useful applications of AI I heard about all began with a clearly defined problem, and only then moved on to the technology.
That is how we approach our own work. Start with the problem, be honest about whether a new tool solves it, and get the detail right when it does.
Thank you, Glasgow
Our thanks to Life Science Integrates, the University of Strathclyde and CMAC for hosting, and to everyone who stopped by our stand. It was a pleasure to meet so many people working on the future of medicines manufacturing.
If we didn't get the chance to speak on the day, we would be glad to continue the conversation. Book a free 30-minute Discovery Call or get in touch at info@bioveritaspartners.com.


